A latest study published by New England Journal of Medicine says, Natrecor (nesiritide),the heart failure medicine is not effectual and is associated to increasing rates of possibly hazardous low blood pressure.
The heart failure drug Natrecor was approved in 2001 to help patients breathe without difficulty. According to the research, since the medicine had no major consequence on breathing problems or any other disease difficulty may also cause low blood pressure.
The study authors have noted that the research has recognized the possible risk and benefits of the drug in people with heart failure who have serious difficulty in breathing a condition also known as dyspnea as the illness is worsening.
To come up with new drugs, we require adequate plan and must have enough data, to rework the whole process so that the doctors and patients are comfortable. Billions of dollars were spent on Natrecor (nesiritide), where as we could have used Lasix which costs penny for single dose. We need to rethink the entire pharmaceutical industry process.
Even though, there were small non-specific effect on reducing death, re-hospitalization and improve dyspnea with nesiritide use for severely worsening heart failure. This result improves clinicians about the possible danger and benefits of Natrecor (nesiritide) in treating such patients.
In 2001 Food and Drug Administration (FDA), U.S. approved nesiritide, the anxiety were raise which may also be associated with worsening of renal functioning and mortality.
It is said that Nesiritide, shall be not be taken away from the market, as it doesn't harm anyone, just because it doesn't hurt people it doesn't means that it should be made available in the market.
The heart failure drug Natrecor was approved in 2001 to help patients breathe without difficulty. According to the research, since the medicine had no major consequence on breathing problems or any other disease difficulty may also cause low blood pressure.
The study authors have noted that the research has recognized the possible risk and benefits of the drug in people with heart failure who have serious difficulty in breathing a condition also known as dyspnea as the illness is worsening.
To come up with new drugs, we require adequate plan and must have enough data, to rework the whole process so that the doctors and patients are comfortable. Billions of dollars were spent on Natrecor (nesiritide), where as we could have used Lasix which costs penny for single dose. We need to rethink the entire pharmaceutical industry process.
Even though, there were small non-specific effect on reducing death, re-hospitalization and improve dyspnea with nesiritide use for severely worsening heart failure. This result improves clinicians about the possible danger and benefits of Natrecor (nesiritide) in treating such patients.
In 2001 Food and Drug Administration (FDA), U.S. approved nesiritide, the anxiety were raise which may also be associated with worsening of renal functioning and mortality.
It is said that Nesiritide, shall be not be taken away from the market, as it doesn't harm anyone, just because it doesn't hurt people it doesn't means that it should be made available in the market.
No comments:
Post a Comment